Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial.

被引：0
|
作者：
Velho, Pedro H. Isaacsson
Girardi, Daniel da Motta
Soares, Andrey
Jardim, Denis Leonardo Fontes
Maluf, Fernando Cotait
Morbeck, Igor Alexandre
Dias, Mariane Fontes
Souza, Vinicius Carrera
E Silva, Adriano Goncalves
de Jesus, Rafaela Gomes
Rebelatto, Taiane Francieli
Bastos, Diogo Assed
机构：
[1] Hosp Moinhos De Vento, Porto Alegre, RS, Brazil
[2] Hosp Sirio Libanes, Brasilia, DF, Brazil
[3] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
[4] Grp Oncoclin, Sao Paulo, SP, Brazil
[5] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
[6] Hosp Benefencia Portuguesa, Sao Paulo, SP, Brazil
[7] Grp Oncoclin, Rio De Janeiro, RJ, Brazil
[8] Hosp Alianca, Oncol DOr, Salvador, BA, Brazil
[9] Inst Canc & Transplante Curitiba ICTr, Curitiba, PR, Brazil
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, RS, Brazil
[11] Hosp Sirio Libanes, Sao Paulo, SP, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS276
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy
    Hoshi, Senji
    Bilim, Vladimir
    Hoshi, Kiyotsugu
    Nakagawa, Takuya
    Sato, Sadanobu
    Sakagami, Rie
    Konno, Masato
    Kudo, Takashi
    Numahata, Kenji
    Sasagawa, Isoji
    CLINICAL CASE REPORTS, 2022, 10 (02):
  • [22] Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer
    Markowski, Mark C.
    Shenderov, Eugene
    Eisenberger, Mario A.
    Kachhap, Sushant
    Pardoll, Drew M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    PROSTATE, 2020, 80 (05): : 407 - 411
  • [23] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [24] PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
    Gongora, A. B. Lara
    Velho, P. Isaacsson
    Marin, J. F. Gomes
    Jardim, D. L. F.
    Inoue, L. T.
    Coser, E. M.
    Buchpiguel, C. A.
    Galiza, F.
    Queiroz, M.
    Schuch, A.
    Grossman, G. B.
    Bettoni, F.
    Camargo, A. A.
    Bastos, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S986 - S986
  • [25] Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
    Pang, J. S-T.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (01) : 76 - 78
  • [27] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
  • [28] A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).
    Fenton, Sarah Elizabeth
    Springsdorf, Rachel
    Kenny, Siobhan
    Bere, Lauren
    Ross, Ashley
    Kocherginsky, Masha
    Hussain, Maha H. A.
    VanderWeele, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
    Vjaters, E.
    Fizazi, K.
    James, N. D.
    Tammela, T. L.
    Matsubara, N.
    Priou, F.
    Beuzeboc, P.
    Lesimple, T.
    Bono, P.
    Kataja, V
    Garcia, J. A.
    Protheroe, A.
    Aspegren, J.
    Joensuu, H.
    Kuss, I
    Thiele, S.
    Fiala-Buskies, S.
    Jones, R. H.
    EUROPEAN UROLOGY, 2022, 81 : S786 - S787
  • [30] Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial
    Mathew, P.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 395 - 396
12345